Market Spotlight: Biliary Tract Cancer
|出版日期||內容資訊||英文 46 Pages
|市場焦點:膽道癌症 Market Spotlight: Biliary Tract Cancer|
|出版日期: 2019年12月31日||內容資訊: 英文 46 Pages||
This Market Spotlight report covers the Biliary Tract Cancer market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2018, there were approximately 397,700 incident cases of biliary tract cancer (BTC) worldwide, and forecasts that number to increase to 425,600 incident cases by 2027. The majority of industry-sponsored drugs in active clinical development for BTC are in Phase II, with one drug in the NDA/BLA phase.
Therapies in development for BTC focus on a wide variety of targets, with the majority being administered via the oral or intravenous routes.
High-impact upcoming events for drugs in the BTC space comprise topline Phase IIa trial results for Xermelo, an expected PDUFA date for pemigatinib, and topline Phase III trial results for Imfinzi and fimaCHEM.
The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 40.7%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There has been only one licensing and asset acquisition deal involving gallbladder and BTC drugs during 2014-19. The exclusive acquisition agreement signed in 2017 between Mundipharma and CellAct for $250m for the acquisition of CAP7-1 was the only deal.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for biliary tract neoplasms have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III.
The US has a substantial lead in the number of biliary tract neoplasms clinical trials globally. The UK leads the major EU markets, while China and South Korea share the top spot in Asia.
Bristol-Myers Squibb has the highest number of ongoing clinical trials for biliary tract neoplasms, with six trials. AstraZeneca and Bristol-Myers Squibb lead industry sponsors with the highest overall number of clinical trials for biliary tract neoplasms.